Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SOD1 | P00441 | 1/20 | 0.32 |
| ▸ | EPOR | P19235 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.31 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13636278 | 0.82 | EPOR (0.33) | NFE2L2TRPV1EPORACHECYP26B1 | |
| SCHEMBL13639106 | 0.79 | CHRNB2 (0.35) | NFE2L2TRPV1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16167476 | 0.77 | NFE2L2 (0.41) | NFE2L2TRPV1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL16167471 | 0.77 | NFE2L2 (0.41) | NFE2L2TRPV1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13639036 | 0.77 | CHRNB2 (0.34) | NFE2L2TRPV1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL13639097 | 0.76 | CHRNB2 (0.33) | NFE2L2TRPV1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL5871109 | 0.70 | NFE2L2 (0.36) | NFE2L2TRPV1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL8000869 | 0.70 | RELA (0.46) | ACHE | |
| SCHEMBL13636281 | 0.69 | TRPV1 (0.33) | NFE2L2TRPV1EPORCYP26B1CYP26A1 | |
| SCHEMBL13845922 | 0.69 | APP (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304385-B2 | Macrocyclic tetrazolyl hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090142299-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | NFE2L2 1970/4885TRPV1 2679/4885CHRNB2 4884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.